Swiss researchers unveiled a fusion protein that combines tumor immune checkpoint disruption with selective immune activation to combat cancer. This bifunctional molecule simultaneously inhibits tumor immune evasion strategies while stimulating antitumor immunity, representing a promising immunotherapeutic strategy. By integrating dual mechanisms in a single therapeutic agent, the approach aims to enhance efficacy and overcome resistance observed in current immunotherapy treatments.